ACUTA CAPITAL PARTNERS, LLC - Q1 2020 holdings

$206 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 32 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 128.6% .

 Value Shares↓ Weighting
AVDL BuyAVADEL PHARMACEUTICALS PLCsponsored adr$20,949,000
+70.7%
2,673,718
+64.5%
10.15%
+234.2%
ADVM BuyADVERUM BIOTECHNOLOGIES INC$16,653,000
+9.3%
1,704,500
+28.9%
8.07%
+113.9%
BLU BuyBELLUS HEALTH INC NEW$10,679,000
+73.5%
1,070,000
+32.1%
5.18%
+239.4%
VSTM NewVERASTEM INC$9,496,0003,720,930
+100.0%
4.60%
ASND BuyASCENDIS PHARMA A Ssponsored adr$7,117,000
+127.4%
63,200
+180.9%
3.45%
+345.2%
BTAI NewBIOXCEL THERAPEUTICS INC$7,040,000315,000
+100.0%
3.41%
CBIO NewCATALYST BIOSCIENCES INC$6,051,0001,384,600
+100.0%
2.93%
APLS BuyAPELLIS PHARMACEUTICALS INC$5,613,000
-2.2%
209,500
+11.7%
2.72%
+91.4%
LSACU NewLIFESCI ACQUISITION CORPunit 03/31/2025$5,599,000560,000
+100.0%
2.71%
MRSN NewMERSANA THERAPEUTICS INC$4,824,000827,500
+100.0%
2.34%
RLMD NewRELMADA THERAPEUTICS INC$3,102,00090,950
+100.0%
1.50%
QURE BuyUNIQURE NV$2,515,000
+40.3%
53,000
+112.0%
1.22%
+174.5%
MRNS NewMARINUS PHARMACEUTICALS INC$2,107,0001,038,000
+100.0%
1.02%
GBT NewGLOBAL BLOOD THERAPEUTICS IN$1,993,00039,000
+100.0%
0.97%
ZFGN BuyZAFGEN INC$1,067,000
-3.9%
1,386,000
+38.6%
0.52%
+88.0%
ABUS NewARBUTUS BIOPHARMA CORP$273,000269,907
+100.0%
0.13%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
IOVANCE BIOTHERAPEUTICS INC24Q1 202321.2%
IRIDEX CORP20Q3 20198.1%
ARROWHEAD PHARMACEUTICALS INC20Q2 20237.9%
IMMUNOMEDICS INC19Q3 202020.6%
VERACYTE INC19Q3 201910.1%
ASCENDIS PHARMA A S18Q2 20207.2%
XENON PHARMACEUTICALS INC18Q3 20224.6%
CAS MED SYS PAR $0.00418Q1 20196.4%
APELLIS PHARMACEUTICALS INC17Q3 202318.4%
KURA ONCOLOGY INC. COMMON STOCK17Q3 20238.1%

View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
ACUTA CAPITAL PARTNERS, LLC Q1 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
BCLS Acquisition Corp.Sold outFebruary 14, 202300.0%
Jiya Acquisition Corp.Sold outFebruary 14, 202300.0%
VistaGen Therapeutics, Inc.Sold outFebruary 14, 202300.0%
Larimar Therapeutics, Inc.Sold outFebruary 15, 202200.0%
CATALYST BIOSCIENCES, INC.Sold outFebruary 14, 202200.0%
Aadi Bioscience, Inc.September 07, 20211,529,4027.2%
Kadmon Holdings, Inc.February 14, 20207,373,3334.6%
IRIDEX CORPSold outNovember 13, 201900.0%
ASSEMBLY BIOSCIENCES, INC.February 14, 2019718,5002.8%
CAS MEDICAL SYSTEMS INCFebruary 14, 20195,263,50818.2%

View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-02-14
SC 13G/A2023-02-14
SC 13G/A2023-02-14
13F-HR2023-02-14
13F-HR2022-11-14

View ACUTA CAPITAL PARTNERS, LLC's complete filings history.

Compare quarters

Export ACUTA CAPITAL PARTNERS, LLC's holdings